Healthcare company ResMed Inc. (RMD) in San Diego, Calif., develops, manufactures, and markets medical devices and cloud-based software applications to diagnose and treat respiratory disorders, such as sleep apnea, chronic obstructive pulmonary disease (COPD), neuromuscular disease, and other chronic diseases. The stock has gained 10.7% in price over the past year and 14% over the past nine months to close yesterday's trading session at $238.52.
The company delivered double-digit growth across top and bottom-line key metrics in its last reported quarter owing to continuing high demand for sleep and respiratory care products, as well as consistent development in its software-as-a-service business.
